MRNA stock rises 6% as the FDA agrees to review its flu vaccine filing after a surprise reversal, with a decision expected by Aug. 5, 2026.

The US Food and Drug Administration has reversed course and will review a new mRNA flu vaccine from Moderna, the pharmaceutical company said...

The US Food and Drug Administration has reversed course and will review a new mRNA flu vaccine from Moderna, the pharmaceutical company said...

Moderna held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu...

THURSDAY, Feb. 19, 2026 — In a sudden reversal, the U.S. Food and Drug Administration (FDA) has agreed to review Moderna’s experimental...

By LAURAN NEERGAARD, AP Medical Writer WASHINGTON (AP) — The Food and Drug Administration will consider whether to approve Moderna’s new flu...

By LAURAN NEERGAARD, AP Medical Writer WASHINGTON (AP) — The Food and Drug Administration will consider whether to approve Moderna’s new flu...

Moderna jumps 4% after EU panel backs mCombriax, its COVID-19-flu combo shot, with phase III data showing stronger immune response vs standalone...

Moderna jumps 4% after EU panel backs mCombriax, its COVID-19-flu combo shot, with phase III data showing stronger immune response vs standalone...

The US Food and Drug Administration will now...